152 related articles for article (PubMed ID: 23719869)
1. Fluticasone-vilanterol combination approved for COPD.
Traynor K
Am J Health Syst Pharm; 2013 Jun; 70(12):1008. PubMed ID: 23719869
[No Abstract] [Full Text] [Related]
2. Vilanterol trifenatate/fluticasone furoate, lomitapide mesylate, and mipomersen sodium.
Hussar DA; Ahmad A
J Am Pharm Assoc (2003); 2013; 53(6):662-70. PubMed ID: 24185435
[No Abstract] [Full Text] [Related]
3. Breo Ellipta: An Inhaled Fluticasone/ Vilanterol Combination for COPD.
Med Lett Drugs Ther; 2013 Sep; 55(1424):69-71, 45-8. PubMed ID: 26839934
[No Abstract] [Full Text] [Related]
4. A systematic review with meta-analysis of fluticasone furoate/vilanterol combination for the treatment of stable COPD.
Rodrigo GJ; Neffen H
Pulm Pharmacol Ther; 2017 Feb; 42():1-6. PubMed ID: 27864038
[TBL] [Abstract][Full Text] [Related]
5. Fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease.
Caramori G; Ruggeri P; Casolari P; Chung KF; Girbino G; Adcock IM
Expert Rev Respir Med; 2017 Dec; 11(12):955-967. PubMed ID: 28956463
[TBL] [Abstract][Full Text] [Related]
6. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.
Pascoe S; Locantore N; Dransfield MT; Barnes NC; Pavord ID
Lancet Respir Med; 2015 Jun; 3(6):435-42. PubMed ID: 25878028
[TBL] [Abstract][Full Text] [Related]
7. Umeclidinium-vilanterol inhaler approved for COPD.
Traynor K
Am J Health Syst Pharm; 2014 Feb; 71(3):174. PubMed ID: 24429003
[No Abstract] [Full Text] [Related]
8. Umeclidinium/vilanterol fixed-dose combination for COPD.
Gras J
Drugs Today (Barc); 2014 Mar; 50(3):231-8. PubMed ID: 24696868
[TBL] [Abstract][Full Text] [Related]
9. ▼Relvar Ellipta for COPD.
Drug Ther Bull; 2014 Jun; 52(6):66-9. PubMed ID: 24904005
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the Impact and Benefits of Fluticasone Furoate/Vilanterol in Individuals with Asthma or COPD: A Mixed-Methods Analysis of Patient Experiences.
Svedsater H; Doll HA; Macey J; Miles G; Bradshaw L; Vanya M
Adv Ther; 2018 Sep; 35(9):1378-1399. PubMed ID: 30105658
[TBL] [Abstract][Full Text] [Related]
11. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
Siler TM; Nagai A; Scott-Wilson CA; Midwinter DA; Crim C
Respir Med; 2017 Feb; 123():8-17. PubMed ID: 28137501
[TBL] [Abstract][Full Text] [Related]
12. Combination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease.
Bollmeier SG; Prosser TR
Ann Pharmacother; 2014 Feb; 48(2):250-7. PubMed ID: 24259654
[TBL] [Abstract][Full Text] [Related]
13. Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis".
Marshall J; Sharma A; Darken P; Ouwens M; Singh B; Tansey-Dwyer D
Adv Ther; 2023 May; 40(5):2549-2555. PubMed ID: 37004641
[No Abstract] [Full Text] [Related]
14. Fluticasone furoate, umeclidinium bromide, and vilanterol as a combination therapy for chronic obstructive pulmonary disease.
Parri G; Nieri D; Roggi MA; Vagaggini B; Celi A; Paggiaro P
Expert Rev Respir Med; 2018 Dec; 12(12):997-1005. PubMed ID: 30463451
[No Abstract] [Full Text] [Related]
15. A Response to: Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis".
Ismaila AS; Haeussler K; Malmenäs M; Sharma R; Compton C; Vogelmeier CF; Han MK; Halpin DMG
Adv Ther; 2023 May; 40(5):2556-2561. PubMed ID: 37004642
[No Abstract] [Full Text] [Related]
16. Relvar Ellipta for asthma.
Drug Ther Bull; 2014 Aug; 52(8):93-6. PubMed ID: 25125553
[TBL] [Abstract][Full Text] [Related]
17. Umeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease.
Blair HA; Deeks ED
Drugs; 2015 Jan; 75(1):61-74. PubMed ID: 25398674
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and Systemic Activity of a New Patent of an Inhaled Corticosteroid/Long-Acting β2-Agonist Combination for Use in Asthma Therapy: Fluticasone Furoate/Vilanterol Trifenatate.
Wolthers OD
Recent Pat Inflamm Allergy Drug Discov; 2015; 9(2):144-50. PubMed ID: 26581314
[TBL] [Abstract][Full Text] [Related]
19. vilanterol + fluticasone (RELVAR Ellipta). Asthma and COPD: yet another beta-2 agonist and corticosteroid combination.
Prescrire Int; 2016 Apr; 25(170):94. PubMed ID: 27186620
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD.
Bhatt SP; Dransfield MT; Cockcroft JR; Wang-Jairaj J; Midwinter DA; Rubin DB; Scott-Wilson CA; Crim C
Int J Chron Obstruct Pulmon Dis; 2017; 12():351-365. PubMed ID: 28176907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
